NEW
YORK, Oct. 29, 2024 /PRNewswire/ -- Hoth
Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage
biopharmaceutical company dedicated to developing new generation
therapies for unmet medical needs, is excited to announce highly
promising early data from a preclinical study of its latest cancer
treatment. The preliminary results demonstrate that the treatment
successfully stabilizes tumor growth with remarkable consistency
across subjects, showing potential as an effective therapeutic
option in oncology. This study was performed and took place under a
sponsored scientific research agreement with NC State
University.
The study measured tumor volumes in treated and untreated
subjects over the course of the experiment. Tumor volume
measurements in the treated group exhibited minimal changes,
suggesting that the treatment effectively inhibited tumor growth.
Additionally, all tumors in the treated animals displayed
remarkable consistency in volume, with standard deviation error
bars barely visible—a strong indication of the treatment's
uniformity and reproducibility in suppressing tumor growth.
"These early findings are incredibly encouraging and demonstrate
that our treatment has the potential to halt tumor progression
consistently across subjects," said Robb Knie, CEO of Hoth Therapeutics. "The
stability and low variability observed in tumor volumes among
treated animals are indicative of a promising therapeutic effect,
and we're excited to move forward with further testing as we
process additional tissue data."
Key observations from the initial data include:
- Stabilized Tumor Growth: Tumor volumes in treated
subjects remained remarkably stable over the course of the study,
suggesting that the treatment may significantly inhibit tumor
growth.
- Consistency Across Subjects: Tumor sizes were highly
consistent across all treated animals, as demonstrated by the
minimal error bars on the graph. This uniform response highlights
the treatment's potential reproducibility and reliability.
- Comparison with Untreated Controls: In contrast,
untreated subjects showed greater variability and an increase in
tumor volume, underscoring the potential efficacy of the treatment
in slowing or halting tumor growth.
As Hoth Therapeutics advances this research, the company will
continue analyzing additional tissue data to further validate these
results. The company is committed to moving forward with the
development of this promising treatment and exploring its full
potential for patients in need of effective cancer therapies.
For more information on Hoth Therapeutics' development programs,
please visit www.hoththerapeutics.com.
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company
dedicated to developing innovative, impactful, and ground-breaking
treatments with a goal to improve patient quality of life. We are a
catalyst in early-stage pharmaceutical research and development,
elevating drugs from the bench to pre-clinical and clinical
testing. Utilizing a patient-centric approach, we collaborate and
partner with a team of scientists, clinicians, and key opinion
leaders to seek out and investigate therapeutics that hold immense
potential to create breakthroughs and diversify treatment options.
To learn more, please visit https://ir.hoththerapeutics.com/.
Forward-Looking Statement
This press release includes forward-looking statements based
upon Hoth's current expectations, which may
constitute forward-looking statements for the purposes of the safe
harbor provisions under the Private Securities Litigation Reform
Act of 1995 and other federal securities laws, and are subject to
substantial risks, uncertainties, and assumptions. These statements
concern Hoth's business strategies; the timing of regulatory
submissions; the ability to obtain and maintain regulatory approval
of existing product
candidates and any other product
candidates we may develop, and the labeling
under any approval we may
obtain; the timing and costs of clinical trials,
and the timing
and costs of other expenses; market acceptance
of our products; the ultimate impact
of the current coronavirus pandemic,
or any other health epidemic, on our business,
our clinical trials, our research programs, healthcare systems, or
the global economy as a whole; our intellectual property; our
reliance on third-party organizations; our competitive position;
our industry environment; our anticipated financial and operating
results, including anticipated sources of revenues; our assumptions
regarding the size of the available market, benefits of our
products, product pricing, and timing of product launches;
management's expectation with respect to future acquisitions;
statements regarding our goals, intentions, plans, and
expectations, including the introduction of new products and
markets; and our cash needs and financing plans. There are a number
of factors that could cause actual events to differ materially from
those indicated by such forward-looking statements. You should not
place reliance on these forward-looking statements, which include
words such as "could," "believe," "anticipate," "intend,"
"estimate," "expect," "may," "continue," "predict," "potential,"
"project" or similar terms, variations of such terms, or the
negative of those terms. Although the Company believes that the
expectations reflected in the forward-looking statements are
reasonable, the Company cannot guarantee such outcomes. Hoth may
not realize its expectations, and its beliefs may not prove
correct.
Actual results may differ materially from those indicated by these forward-looking statements as a result of
various important factors, including, without limitation,
market conditions and the
factors described in the section titled "Risk
Factors" in Hoth's most recent Annual Report on Form 10-K and
Hoth's other filings made with the U. S. Securities and Exchange
Commission. All such statements speak only as of the date made.
Consequently, forward-looking statements should be regarded solely
as Hoth's current plans, estimates, and beliefs. Investors should
not place undue reliance on forward-looking statements. Hoth cannot
guarantee future results, events, levels of activity, performance,
or achievements. Hoth does not undertake and specifically declines
any obligation to update, republish, or revise any forward-looking
statements to reflect new information, future events, or
circumstances or to reflect the occurrences of unanticipated
events, except as may be required by applicable law.
Investor Contact:
LR Advisors LLC
Email:
investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download
multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-announces-update-on-cancer-therapeutic-ht-kit-results-suggesting-the-treatment-effectively-inhibited-tumor-growth-in-preclinical-treatment-study-302290406.html
SOURCE Hoth Therapeutics, Inc.